ATB Stock Overview
Produces and sells medicinal products in Romania. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Antibiotice S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RON 2.44 |
| 52 Week High | RON 3.44 |
| 52 Week Low | RON 1.36 |
| Beta | 0.14 |
| 11 Month Change | -22.04% |
| 3 Month Change | -16.72% |
| 1 Year Change | 74.91% |
| 33 Year Change | 309.40% |
| 5 Year Change | 388.00% |
| Change since IPO | 2,861.60% |
Recent News & Updates
Recent updates
Is Antibiotice (BVB:ATB) Using Too Much Debt?
Nov 23
Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost
Jun 07Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump
Jan 30We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease
Jan 13These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely
Aug 16Is Antibiotice (BVB:ATB) A Risky Investment?
Jun 08These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively
Mar 10Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield
Feb 11Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)
Jan 12Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 16
Is Antibiotice (BVB:ATB) Using Too Much Debt?
Nov 24Shareholder Returns
| ATB | RO Pharmaceuticals | RO Market | |
|---|---|---|---|
| 7D | -8.6% | 1.4% | -2.1% |
| 1Y | 74.9% | 7.2% | 7.2% |
Return vs Industry: ATB exceeded the RO Pharmaceuticals industry which returned 7.2% over the past year.
Return vs Market: ATB exceeded the RO Market which returned 7.2% over the past year.
Price Volatility
| ATB volatility | |
|---|---|
| ATB Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in RO Market | 10.7% |
| 10% least volatile stocks in RO Market | 2.4% |
Stable Share Price: ATB's share price has been volatile over the past 3 months compared to the RO market.
Volatility Over Time: ATB's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of RO stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1955 | 1,352 | Ioan Nani | www.antibiotice.ro |
Antibiotice S.A. produces and sells medicinal products in Romania. The company produces medicines for a range of therapeutic areas, such as cardiovascular system, alimentary tract and metabolism, musculo-skeletal system, nervous system, antiinfectives, respiratory system, dermatological, food supplements, sensory organs, genito-urinary apparatus and sexual hormones, varia, and blood and blood forming organs, as well as veterinary medicinal products. It offers its products in the form of sterile injectable powders, capsules, tablets, ointments, gels, creams, and suppositories.
Antibiotice S.A. Fundamentals Summary
| ATB fundamental statistics | |
|---|---|
| Market cap | RON 1.77b |
| Earnings (TTM) | RON 92.29m |
| Revenue (TTM) | RON 657.89m |
17.7x
P/E Ratio2.5x
P/S RatioIs ATB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATB income statement (TTM) | |
|---|---|
| Revenue | RON 657.89m |
| Cost of Revenue | RON 242.29m |
| Gross Profit | RON 415.60m |
| Other Expenses | RON 323.30m |
| Earnings | RON 92.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 63.17% |
| Net Profit Margin | 14.03% |
| Debt/Equity Ratio | 13.8% |
How did ATB perform over the long term?
See historical performance and comparison